Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis

• DOI: 10.1371/journal.pone.0243783
• Publication Date: 2020-12-14T18:33:03Z
• Authors: Fu-Shun Yen; Jung-Nien Lai; James Cheng-Chung...; Lu-Ting Chiu; Chii-Min Hwu; Ming-Chih Hou; Chih-Cheng Hsu
• Keywords: Sulfonylurea

This study aimed to investigate the long-term outcomes of sulfonylurea (SU) use in patients with T2DM and compensated liver cirrhosis. From January 1, 2000, December 31, 2012, we selected data 3781 propensity-score-matched SU users nonusers from Taiwan’s National Health Insurance Research Database. The mean follow-up time for this was 5.74 years. Cox proportional hazards models robust sandwich standard error estimates were used compare risks main between nonusers. incidence mortality during 3.24 4.09 per 100 person-years nonusers, respectively. adjusted hazard ratios 95% confidence intervals all-cause mortality, major cardiovascular events, decompensated cirrhosis relative 0.79 (0.71–0.88), 0.69 (0.61–0.80), 0.82 (0.66–1.03), SU-associated lower death events seemed have a dose–response trend. population-based cohort demonstrated that associated compared non-use SUs may be useful glycemic management